Introduction
============

CRC is a common malignant cancer worldwide, and its high mortality makes it the second leading cause of cancer-related deaths due to its poor prognosis after cancer progression.[@b1-ott-11-8481] In China, CRC mortality rate has been ranked fifth in malignant tumor mortality, seriously endangering human health.[@b2-ott-11-8481],[@b3-ott-11-8481] The occurrence of colon cancer is closely related to diet, environment, heredity, and other factors.[@b4-ott-11-8481] The prevention and treatment of colon cancer has received increasing attention in recent years. When the balance between the oncogene and the tumor suppressor gene is disrupted, the expression of the oncogene that controls cell proliferation is sustained or upregulated and the tumor suppressor gene is not expressed or is inactivated; thus, the cancerous cell escapes the control of the body's immune mechanism and forms a tumor.[@b5-ott-11-8481] This leads to the deterioration and metastasis of cells. The detection of cancer-related genes is of clinical significance in predicting the occurrence, development, therapeutic effect, and prognosis of colon cancer.[@b6-ott-11-8481]--[@b8-ott-11-8481]

The sex determining region Y (SRYSOX18) is a member of the Sox transcription factor subfamily which plays an important role in the development of blood and lymphatic vessels. Mutations of the gene or abnormal expression are related to tumorigenesis and tumor development. Recently, studies reported that abnormal expression of SOX18 was observed in prostate cancer,[@b9-ott-11-8481] breast cancer,[@b10-ott-11-8481] non-small-cell lung carcinoma,[@b11-ott-11-8481] non-melanoma skin cancer,[@b12-ott-11-8481] and ovarian cancer.[@b13-ott-11-8481] The role of SOX18 in CRC remains unknown.

Previously, we found abnormal SOX18 expression in CRC tissues, and patients with higher expression of SOX18 had a lower survival rate. SOX18 also regulated CRC cell growth in vitro and in vivo. The present study aimed at exploring SOX18 expression in CRC samples and the correlation between SOX18 and CRC prognosis.

Materials and methods
=====================

Patients and tissue samples
---------------------------

Sixty samples of CRC tissues and benign tissues surgically removed from patients at The First Affiliated Hospital of Gannan Medical University were collected from 2013 to 2016. Adjacent normal tissues were also collected as negative controls. Preoperative clinical and pathological follow-up data were completed by all patients. Ethical approval for the study was provided by the Ethics Committee of The First Affiliated Hospital of Gannan Medical University. Written informed consent was obtained from the study subjects.

IHC
---

Tissue sections were initially deparaffinized, rehydrated, and then heated in EDTA (pH 8.0); antigen retrieval was performed in 10 mM citrate buffer for 5 minutes at 100°C. The incubation with SOX18 antibody (1:200; cat. no ab109194, Abcam, Cambridge, MA, USA) or Ki67 (1:400; cat. no Ab833, Abcam, USA) was performed at room temperature for 1 hour, followed by incubation with biotin-labeled secondary antibodies. Slides were then developed using DAB solution and counterstained with hematoxylin staining (BASO, Zhuhai, China). Immunohistochemical signals were calculated with positive staining cells under a microscope (Olympus Corporation, Tokyo, Japan) with magnification of 200×.

Cell culture
------------

NCM460 human colon epithelial cells were obtained from the Cell Engineering Research Center of The Fourth Military Medical University (Xi'an, Shanxi, China) and cultured in RPMI-1640 (Gibco) containing 10% FBS, 10 ng/mL EGF, 1% insulin (First Biological and Chemical Medication Co., LTD, Shanghai, China), 5 µg/mL hydrocortisone (The Third Pharmaceutical Company, Beijing, China), and 1% penicillin/streptomycin, at 37°C in a humidified atmosphere of 5% CO~2~. The use of the NCM460 cell line was approved by the Ethics Committee of The First Affiliated Hospital of Gannan Medical University. Human colon cancer cells (HT-29, HCT-116, SW620, and OUMS23) were purchased from the SUER Bio-Technique Co. Ltd. in Shanghai, China and cultured in DMEM (St Louis, MO, USA) containing 10% FBS and 1% penicillin-streptomycin at 37°C in a humidified atmosphere of 5% CO~2~.

Cell transfection
-----------------

HT-29 and SW620 cells were seeded onto 6-well culture plates at a density of 3×10^5^ cells/well. SOX18, SOX18 shRNA, and the respective negative controls (all purchased from Shanghai GenePharma Co., Ltd, Shanghai, China) were then transfected into cells at 50%--60% confluence using Lipofectamine™ 2000 (Invitrogen, Shanghai, China), following the manufacturer's protocol. The targeted sequences for shRNA-SOX18-1 and shRNA-SOX18-2 were 5′-GCGGCCCTTCGTGGAGGAAGC-3′ and 5′-GGCTGCGCGTGCAGCACTTGC-3′, respectively. After 48 hours, transfected cells were collected and processed for subsequent experiments.

CCK-8 assay
-----------

Cell viability was evaluated by the CCK-8 assay. Briefly, 48 hours after transfection, HT-29 and SW620 cells were seeded at a density of 4×10^3^ cells/well in 96-well plates and incubated for 0, 24, 48, and 72 hours. Subsequently, 20 µL of CCK-8 was added to each well, and the plates were incubated for 1 hour. The optical density was read at 450 nm using a microplate reader (Thermo, Fisher Scientific, Waltham, MA, USA). All experimental concentrations were assessed in triplicate.

Colony formation assay
----------------------

The colony formation assay was used to assess the clonogenic ability of transfected cells. CRC cells (2×10^3^/well) were trypsinized in a single-cell suspension and seeded in 6-well dishes. Cells were maintained in RPMI-1640 supplemented with 10% FBS for approximately two weeks. Visible colonies were fixed in 4% paraformaldehyde for 4 hours at 37°C and stained with 0.5% crystal violet for 2 hours at 37°C (Beyotime Institute of Biotechnology, Haimen, China). Colony numbers were counted under a light microscope (Olympus Corporation, Japan).

Cell cycle analysis
-------------------

Flow cytometry was employed for the analysis of the cell cycle. After transfection, cells were harvested and fixed overnight in ice-cold 70% ethanol (stored at -20°C). Afterwards, cells were washed with PBS prior to re-suspension in DNA-staining solution \[40 µg/mL PI, 250 µg/mL RNase in PBS with 2 mM EDTA\] for 30 minutes at 37°C. Analysis was performed using a flow cytometer (FACSCalibur, BD Biosciences).

Apoptosis analysis
------------------

The apoptosis levels of HT-29 and SW620 cells transfected with SOX18, shSOX18, or negative control RNA were measured by flow cytometry. HT-29 and SW620 cells transfected with SOX18 or negative control RNA were then treated with cisplatin (30 µg/mL). The detection procedures for overall cell apoptosis were similar to those already described up to the ethanol fixation step, with slight modifications in the cell numbers. Briefly, ethanol-fixed cells (1×10^6^ cells/well) were harvested in centrifuge tubes, washed and detached in 2 PBS with 2 mM EDTA, and centrifuged at 15,000 *g* for 5 minutes. Cells were then stained with 250 µL of hypotonic fluorochrome solution (50 µg PI, 0.1% sodium citrate, and 0.1% Triton X-100 in PBS) with RNase A (100 U/mL; BD PharMingen) for 30 minutes in the dark at room temperature. Measurements were made using a flow cytometer (BD Influx; BD Biosciences, Franklin Lakes, NJ, USA). The B3 quadrant represented viable cells; B2 and B4 quadrants represented apoptotic cells.

RNA isolation and qRT-PCR
-------------------------

Gene expression was evaluated by qRT-PCR (Trans-Start Top Green qPCR SuperMix, TransGen Biotech Co., LTD, Beijing, China). Cells were seeded in 6-well plates at a density of 5×10^5^ cells/well, cultured overnight, and treated with either SOX18 or shRNA-SOX18 for 48 hours. Total RNA was extracted from cells using TRIzol reagent (Invitrogen) according to the manufacturer's protocol, and 2 µg were used for reverse-transcription with the TransCript One-step gDNA Removal and cDNA Synthesis SuperMix (TransGen Biotech, Beijing, China). Expression of SOX18 in HT-29 and in SW620 cells was detected by qRT-PCR with the following cycling parameters: 5 minutes at 95°C, followed by 40 cycles at 95°C for 15 seconds, 60°C for 30 seconds, and 72°C for 30 seconds. The primers used for the amplification of the indicated genes were designed using the Primer Express Software (Applied Biosystems, Foster City, CA, USA): 5′-CGCGTGTATGTTTGGTTC-3′ and 5′-ATGTAACCCTGGCAACTC-3′ for SOX18 and 5′-ACCRCGAAGACTGTGGATGG-3′ and 5′-TCAGCTC AGGGATGACCTTG-3′ for GAPDH. The relative expression level was calculated as follows: Relative expression level = 2^−ΔΔCt^, where ΔCt = Ct (gene of interest) − Ct (housekeeping gene).[@b14-ott-11-8481] GAPDH was used as the housekeeping gene. All reactions were performed in triplicate.

Western blotting analysis
-------------------------

Total protein lysates were resolved by 10% SDS-PAGE and transferred to polyvinyl difluoride membranes (EMD Millipore, Burlington, MA, USA). After blocking with 5% non-fat dry milk in Tris-buffered saline containing 0.1% Tween-20 (TBS-T) for 30 minutes, membranes were washed four times in TBS-T and incubated overnight at 4°C with primary antibodies anti-SOX18 or anti-GAPDH at 1:1,000 (ab66145 and ab8245, respectively; Cambridge, MA, USA). After extensive washing, membranes were incubated with horseradish peroxidase-linked goat polyclonal anti-rabbit IgG secondary antibody, at a dilution of 1:2,000, for 1 hour at room temperature. Immunoreactivity was detected by enhanced chemiluminescence (ECL Kit, Pierce Biotechnology, Waltham, MA, USA) and captured on a radiographic film. Expression of GAPDH served as loading control.

In vivo xenograft experiments
-----------------------------

Male BALB/c nude mice (6-week-old; n=6) were purchased from Beijing (HFK Bioscience Co. Ltd. Beijing, China) and maintained under pathogen-free conditions, with the approval of the Ethics Committee of The First Affiliated Hospital of Gannan Medical University. For tumor propagation analysis, 1×10^7^ HT-29 tumor cells were subcutaneously injected into BALB/c nude mice. The tumor volume was calculated using the formula v=πab^2^/6 (where v is volume, a is tumor length, and b is tumor width) at the indicated time points. Tumor weight was measured at week four post-injection. Animal experiments were performed in accordance with the relevant guidelines and regulations of the Animal Care and Use Committees at The First Affiliated Hospital of Gannan Medical University.

Statistical analysis
--------------------

All results are presented as the mean ± SD of three independent experiments, and the data were processed with SPSS 13.0 software. Pearson's *χ*^2^ tests were used for the analysis of the correlation between clinicopathological features and SOX18 expression in CRC patients. Kaplan--Meier survival analysis was used for the analysis of the survival rate, and the *P*-value was calculated by the log-rank test. Data for multiple comparisons were subjected to one-way ANOVA and chi-square tests. *P*\<0.05 was considered statistically significant.

Results
=======

Increased expression of SOX18 in CRC patients and cell lines
------------------------------------------------------------

We first analyzed the expression of SOX18 in CRC tissues and adjacent non-tumor tissues by qRT-PCR. We found that the expression of SOX18 was significantly increased in CRC tissues compared to that in normal tissues (*P*\<0.0001, [Figure 1A](#f1-ott-11-8481){ref-type="fig"}). The expression of SOX18 in CRC tissues and non-tumor tissues was also examined by IHC with pairs of CRC samples. As shown in [Figure 1B](#f1-ott-11-8481){ref-type="fig"}, the expression of SOX18 in CRC tissues was higher than that in non-tumor tissues. To further evaluate the clinicopathological signifi-cance of SOX18 levels in patients with CRC, the 60 samples from patients were divided into two subgroups based on the mean value of SOX18 expression: low SOX18 group (34 cases) and high SOX18 group (26 cases). As displayed in [Table 1](#t1-ott-11-8481){ref-type="table"}, SOX18 levels in CRC tissues were positively associated with advanced clinical stages, vascular invasion, and lymph node metastasis. Furthermore, patients with higher expression of SOX18 had a lower survival rate ([Figure 1C](#f1-ott-11-8481){ref-type="fig"}).

In addition, mRNA and protein levels of SOX18 in human colon epithelial cells (NCM460) and CRC cells (HT-29, HCT-116, SW620, and OUMS23) were also detected. As presented in [Figure 1D and E](#f1-ott-11-8481){ref-type="fig"}, expression of SOX18 increased remarkably in CRC cell lines compared to that in human colon epithelial cells (*P*\<0.01). The results indicate that SOX18 might act as an oncogene in CRC.

Overexpression of SOX18 promoted cell proliferation and suppressed cell apoptosis
---------------------------------------------------------------------------------

To explore the biological role of SOX18 in CRC, HT-29 and SW620 cells were transfected with SOX18 overexpression or negative control plasmids. After transfection for 48 hours, the expression of SOX18 in HT-29 and SW620 cells was detected by qRT-PCR and Western blot ([Figure 2A and B](#f2-ott-11-8481){ref-type="fig"}). To induce effective cell apoptosis, HT-29 and SW620 cells transfected with SOX18 overexpression or negative control plasmids were treated with cisplatin. Cell proliferation was assessed by CCK-8 and colony formation assays. Cell cycle and apoptosis were determined by flow cytometry and annexin V/PI staining, respectively. As shown in [Figure 2C and D](#f2-ott-11-8481){ref-type="fig"}, cell viability and colony formation were significantly promoted by SOX18 overexpression compared to the cells in control groups (*P*\<0.01). Upregulation of SOX18 also accelerated the progression from G0/G1 to S phase in CRC cells ([Figure 2E](#f2-ott-11-8481){ref-type="fig"}). Annexin V/PI staining showed that SOX18 over-expression effectively inhibited cell apoptosis in HT-29 and SW620 cells ([Figure 2F](#f2-ott-11-8481){ref-type="fig"}). These results reveal that SOX18 has a carcinogenic role in CRC.

Downregulation of SOX18 inhibited cell proliferation and induced cell apoptosis
-------------------------------------------------------------------------------

To explore further the function of SOX18 in CRC, HT-29 and SW620 cells were transfected with shSOX18-1, shSOX18-2, or negative control (shControl). Forty-eight hours after transfection, SOX18 expression in HT-29 and SW620 cells was detected by qRT-PCR and Western blot. Compared to control groups, cells transfected with shSOX18-1 and shSOX18-2 clearly downregulated SOX18 (*P*\<0.05), especially shSOX18-1 ([Figure 3A and B](#f3-ott-11-8481){ref-type="fig"}). Therefore, this sequence was selected for subsequent experiments. CCK-8 and colony formation assays indicated that cell proliferation was significantly reduced by shSOX18 transfection in CRC cells (*P*\<0.01; [Figure 3C and D](#f3-ott-11-8481){ref-type="fig"}). Cell cycle was then evaluated by flow cytometry, and the results indicate that silencing of SOX18 expression effectively induced G0/G1 phase arrest compared to CRC cells transfected with shControl ([Figure 3E](#f3-ott-11-8481){ref-type="fig"}). Results of the annexin V/PI staining revealed that cell apoptosis was increased 1.67 and 2.33 fold in HT-29 and SW620 cells transfected with shSOX18, respectively (*P*\<0.01; [Figure 3F](#f3-ott-11-8481){ref-type="fig"}). The results demonstrate that downregulation of SOX18 can determine progression of CRC.

Tumor-suppressive effect of shSOX18 in vivo
-------------------------------------------

The biological effects of SOX18 on CRC development were addressed by performing a xenograft mouse model. HT-29 cells were transfected with shControl or shSOX18 and then implanted subcutaneously into nude mice. Tumor growth was examined every 7 days. It was observed that downregulation of SOX18 notably delayed tumor growth in vivo ([Figure 4A](#f4-ott-11-8481){ref-type="fig"}). At 35 days post-implantation, nude mice were sacrificed, and tumors were harvested and weighed. As shown in [Figure 4B and C](#f4-ott-11-8481){ref-type="fig"}, silencing of SOX18 expression clearly decreased tumor size and weight (*P*\<0.001). Finally, the expression of Ki67, an important biological index of cell proliferation, was determined by IHC. The expression of Ki67 was significantly decreased in the shSOX18 group compared to that in the shControl group ([Figure 4D](#f4-ott-11-8481){ref-type="fig"}). The results prove that SOX18 can promote CRC development in vivo.

Discussion
==========

In recent years, a number of diagnostic strategies and therapeutic methods have been followed to treat CRC. However, the overall survival rate of patients with CRC remains low due to tumor recurrence and metastasis.[@b15-ott-11-8481],[@b16-ott-11-8481] Therefore, in order to develop a novel and effective therapeutic approach for CRC treatment, there is an urgent need to fully understand the molecular mechanisms that regulate CRC initiation and progression. SOX18 is a member of the Sox transcription factor subfamily, which plays an important role in the development of blood and lymphatic vessels. Previous studies reported that abnormal expression of SOX18 was observed in a wide variety of cancers.[@b10-ott-11-8481] Yin et al reported that SOX18 was overexpressed in prostate cancer and that it might regulate the malignant capacity of cells via the upregulation of TCF1, c-Myc, cyclin D1, and MMP-7.[@b9-ott-11-8481] Ornat et al reported that SOX18 played a crucial role in the development of squamous cell carcinoma and basal cell carcinoma.[@b12-ott-11-8481] Jethon et al indicated that expression of SOX18 was increased in non-small-cell lung cancer and cytoplasmic SOX18 expression was correlated with poor patient outcome.[@b11-ott-11-8481] In the present study, we observed that the expression of SOX18 was significantly increased in CRC tissues. Additionally, we discovered that SOX18 expression levels were significantly correlated with AJCC stage, vascular invasion, depth of invasion, lymph node metastasis, and distant metastasis, which demonstrates that SOX18 overexpression is positively correlated with CRC progression. We also found that CRC patients with higher expression of SOX18 present decreased survival rates. Furthermore, it was also noted that expression of SOX18 in CRC cell lines was higher than that in the human colon epithelial cells. Based on the above results, we propose that SOX18 may exert a cancer-promoting role in CRC progression.

Excessive cell proliferation is one of the manifestations of malignant tumors.[@b17-ott-11-8481] Wang et al demonstrated that SOX18 promoted the proliferation and metastasis of hepatocellular carcinoma cells by regulating focal adhesion and chemokine signaling pathways.[@b18-ott-11-8481] Therefore, the effects of SOX18 upregulation or downregulation on CRC cell viability were examined by CCK-8 and colony formation assays. Results showed that cell proliferation and clonogenic ability were noticeably inhibited by SOX18 knockdown and significantly promoted by SOX18 overexpression. We then examined whether cell growth inhibition was associated with cell cycle progression and cell apoptosis. Cell cycle and cell apoptosis of CRC cells transfected with SOX18 or shSOX18 were evaluated by flow cytometry and annexin V/PI staining, respectively. In our study, cell cycle arrest and cell apoptosis were markedly induced by shSOX18 in CRC cells. On the contrary, upregulation of SOX18 dramatically promoted cell cycle progression and reduced cell apoptosis ratio. Our results reveal, for the first time, that ectopic expression of SOX18 might give rise to oncogenesis in CRC.

Previous in vivo studies indicated that SOX18 could delay tumor growth in prostate cancer.[@b9-ott-11-8481] Therefore, we evaluated the biological role of SOX18 in CRC development by performing a xenograft mouse model. Our results revealed that downregulation of SOX18 notably delayed tumor growth, as well as decreased tumor size and weight. The expression of Ki67, a nuclear antigen associated with proliferation, is closely related to the occurrence and development of many tumor diseases.[@b19-ott-11-8481]--[@b21-ott-11-8481] Melling et al showed that Ki67 acts as an independent prognostic biomarker in CRC.[@b22-ott-11-8481] In the present study, the expression of Ki67 in tumor tissues of the xeno-graft mouse model was analyzed, and the results showed that silencing of SOX18 effectively inhibited Ki67 expression in CRC tissue. These findings suggest that SOX18 may exert an oncogenic role in CRC progression.

In conclusion, the results of the present study indicate that SOX18 is significantly upregulated in CRC tissues and cell lines compared to that in normal tissues and cells and that SOX18 is associated with CRC cancer risk, survival rate, and cell growth in vitro and in vivo. Our findings suggest that SOX18 may act as a novel diagnostic and prognostic marker and a novel therapeutic target for CRC treatment.
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![Expression of SOX18 in CRC tissues and cell lines.\
**Notes:** (**A**) mRNA levels of SOX18 in 60 paired CRC samples and normal non-tumor tissues, as assessed by qRT-PCR. (**B**) Protein expression of SOX18 in CRC tissues and normal tissues determined by immunohistochemistry. Magnification: 200×. (**C**) Survival rates of patients with CRC with high and low SOX18 levels by Kaplan--Meier survival analysis. (**D**) mRNA levels of SOX18 in human colon epithelial cells (NCM460) and CRC cells (HT-29, HCT-116, SW620, and OUMS23) detected by qRT-PCR. (**E**) Protein levels of SOX18 in human colon epithelial cells (NCM460) and CRC cells (HT-29, HCT-116, SW620, and OUMS23) detected by Western blotting. Data are presented as mean ± SD. \*\**P*\<0.01, \*\*\**P*\<0.001 vs NCM460 cell line.\
**Abbreviations:** CRC, colorectal cancer; SOX18, region, sex determining region Y (SRY)-box 18; qRT-PCR, quantitative real-time PCR.](ott-11-8481Fig1){#f1-ott-11-8481}

![Effect of SOX18 on cell proliferation, cell cycle, and apoptosis.\
**Notes:** (**A**, **B**) HT-29 and SW620 cells were transfected with SOX18 overexpression or negative control plasmids and then treated with cisplatin. The transfection efficiency was examined by qRT-PCR and Western blot. (**C**, **D**) Cell proliferation was determined by CCK-8 and cell colony formation. (**E**) Cell cycle was analyzed by flow cytometry. (**F**) Cell apoptosis was measured in HT-29 and SW620 cells transfected with SOX18 overexpression or negative control by staining with annexin V/PI. Data are presented as mean ± SD. \*\**P*\<0.01, \*\*\**P*\<0.001 vs Control.\
**Abbreviations:** CCK-8, cell counting kit-8; PI, propidium iodide; SOX18, sex determining region Y (SRY)-box 18.](ott-11-8481Fig2){#f2-ott-11-8481}

![Effect of silencing SOX18 on cell proliferation, cell cycle, and apoptosis.\
**Notes:** (**A**, **B**) HT-29 and SW620 cells were transfected with shSOX18 or negative control (shControl). The transfection efficiency was examined by qRT-PCR and Western blot. (**C**, **D**) Cell proliferation was determined by CCK-8 and cell colony formation. (**E**) Cell cycle was analyzed by flow cytometry. (**F**) Cell apoptosis was measured in HT-29 and SW620 cells transfected with shSOX18 or negative control by staining with annexin V/PI. Data are presented as mean ± SD. \**P*\<0.05, \*\**P*\<0.01, \*\*\**P*\<0.001 vs shControl.\
**Abbreviations:** CCK-8, cell counting kit-8; PI, propidium iodide; SOX18, sex determining region Y (SRY)-box 18.](ott-11-8481Fig3){#f3-ott-11-8481}

![The role of SOX18 on CRC progression in vivo.\
**Notes:** (**A**) Tumor growth curves were established by measuring tumor volume every 7 days, for 28 days after injection. (**B**, **C**) Tumor weights isolated from nude mice in each treatment group were determined on day 28 after injection. (**D**) Expression of Ki67 in tumor tissues was assessed by IHC. \*\*\**P*\<0.001 vs shControl.\
**Abbreviations:** CRC, colorectal cancer; SOX18, sex determining region Y (SRY)-box 18.](ott-11-8481Fig4){#f4-ott-11-8481}

###### 

Association between clinicopathological features and SOX18 expression in 60 patients with CRC

  Characteristics         Number of patients   SOX18 Low expression (≤medium)   SOX18 High expression (≥medium)   *P*-value
  ----------------------- -------------------- -------------------------------- --------------------------------- -----------
  Number                  60                   34                               26                                
  Ages (years)                                                                                                    0.660
   \<60                   25                   15                               10                                
   ≥60                    35                   19                               16                                
  Gender                                                                                                          0.944
   Female                 32                   18                               14                                
   Male                   28                   16                               12                                
  Location                                                                                                        0.651
   Left                   32                   19                               13                                
   Right                  28                   15                               13                                
  Tumor size                                                                                                      0.944
   ≤3                     28                   16                               12                                
   \>3                    32                   18                               14                                
  AJCC stage                                                                                                      \<0.001
   I                      21                   18                               3                                 
   II                     14                   10                               4                                 
   III                    21                   5                                16                                
   IV                     4                    1                                3                                 
  Differentiation                                                                                                 0.472
   Well                   18                   10                               8                                 
   Moderately             27                   15                               12                                
   Poorly                 15                   9                                6                                 
  Vascular invasion                                                                                               0.002
   Yes                    28                   10                               18                                
   No                     32                   24                               8                                 
  Depth of invasion                                                                                               0.036
   T~1~                   8                    6                                2                                 
   T~2~                   11                   8                                3                                 
   T~3~                   24                   13                               11                                
   T~4~                   17                   7                                10                                
  Lymph node metastasis                                                                                           0.001
   N~0~                   26                   21                               5                                 
   N~1~                   20                   10                               10                                
   N~2~                   14                   3                                11                                
  Distant metastasis                                                                                              0.015
   M~0~                   46                   30                               16                                
   M~1~                   14                   4                                10                                

**Abbreviations:** AJCC stage, American Joint Committee on Cancer; CRC, colorectal cancer; SOX18, sex determining region Y (SRY)-box 18.
